Freakonomics Radio 433. How Are Psychedelics and Other Party Drugs Changing Psychiatry?
Oct 1, 2020
In this enlightening discussion, psychiatrist James Murrow explores ketamine's groundbreaking effects on depression, while Rachel Yehuda reveals the potential of MDMA-assisted therapy for PTSD. Yasmin Hurd dives into the role of CBD in combating opioid addiction. Together, they unveil how recreational drugs are transforming psychiatry, addressing both their promise and regulatory challenges. The conversation highlights the shift in perception regarding these substances and their increasing relevance in mental health treatment.
AI Snips
Chapters
Books
Transcript
Episode notes
Ketamine Research Beginnings
- James Murrow became involved in ketamine research during his residency at Mount Sinai.
- He was initially drawn to the work of Dennis Charney, who pioneered early research on ketamine's antidepressant effects.
Exploring MDMA for PTSD
- Rachel Yehuda has studied PTSD for over 30 years and found traditional treatments lacking.
- This led her to explore MDMA-assisted psychotherapy as a potential alternative treatment.
CBD's Potential for Addiction
- Yasmin Hurd's research on early cannabis use revealed increased risks for later substance use disorders.
- However, studying CBD showed the opposite effect, reducing drug-seeking behavior in rat models.
